Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

2.

Haroche

J

,

Charlotte

F

,

Arnaud

L

, et al.

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

.

Blood

.

2012

;

120

(

13

):

2700

-

2703

.

3.

Diamond

EL

,

Subbiah

V

,

Lockhart

AC

, et al.

Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study

.

JAMA Oncol

.

2018

;

4

(

3

):

384

-

388

.

4.

Reiner

AS

,

Durham

BH

,

Yabe

M

, et al.

Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms

.

Br J Haematol

.

2023

;

203

(

3

):

389

-

394

.

5.

Goyal

G

,

Shah

MV

,

Call

TG

,

Litzow

MR

,

Hogan

WJ

,

Go

RS

.

Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease

.

JAMA Oncol

.

2017

;

3

(

9

):

1253

-

1256

.

6.

Cella

DF

,

Tulsky

DS

,

Gray

G

, et al.

The functional assessment of cancer therapy scale: development and validation of the general measure

.

J Clin Oncol

.

1993

;

11

(

3

):

570

-

579

.

7.

National Cancer Institute

.

Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

. Accessed 1 December 2024. https://healthcaredelivery.cancer.gov/pro-ctcae.

8.

Holzner

B

,

Kemmler

G

,

Cella

D

, et al.

Normative data for functional assessment of cancer therapy–general scale and its use for the interpretation of quality of life scores in cancer survivors

.

Acta Oncol

.

2004

;

43

(

2

):

153

-

160

.

9.

Cohen Aubart

F

,

Emile

JF

,

Carrat

F

, et al.

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

.

Blood

.

2017

;

130

(

11

):

1377

-

1380

.

10.

Mittapalli

RK

,

Vaidhyanathan

S

,

Dudek

AZ

,

Elmquist

WF

.

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

.

J Pharmacol Exp Ther

.

2013

;

344

(

3

):

655

-

664

.

11.

Diamond

EL

,

Durham

BH

,

Ulaner

GA

, et al.

Efficacy of MEK inhibition in patients with histiocytic neoplasms

.

Nature

.

2019

;

567

(

7749

):

521

-

524

.

https://doi.org/10.1038/s41375-025-02526-5

12.

Acosta-Medina

AA

,

Abeykoon

JP

,

Zanwar

S

, et al.

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants

.

Leukemia

.

Published online 11 February 2025

.